Physician profile
Lyndsay R Shipp
NPI 1063724987
$246,345.35
in general payments reported to CMS, 2019-2025
29 companies · $142K in 2025
The $142K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $6,338 · 2021: $9,701 · 2022: $13K · 2023: $3,824 · 2024: $61K · 2025: $142K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $170K · Travel and Lodging: $21K · Food and Beverage: $11K · Consulting Fee: $4,725 · Education: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $169,656.32 |
| Travel and Lodging | $21,355.23 |
| Food and Beverage | $10,893.66 |
| Consulting Fee | $4,725.00 |
| Education | $436.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $151,059.50 | 2021-2025 | Acthar |
| Amgen INC. | $39,973.41 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $29,426.35 | 2019-2025 | |
| Celgene Corporation | $9,396.35 | 2019 | |
| Abbvie INC. | $3,596.27 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Allergan, INC. | $2,820.76 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $1,504.71 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $1,171.31 | 2020-2025 | Tremfya |
| Revance Therapeutics, INC. | $951.85 | 2024-2025 | Daxxify |
| Ucb, INC. | $930.90 | 2020-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $810.02 | 2019-2023 | |
| Leo Pharma INC. | $704.46 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $631.10 | 2019-2025 | Dupixent |
| Genzyme Corporation | $610.93 | 2019-2025 | |
| Galderma Laboratories, L.P. | $500.43 | 2019-2025 | Nemluvio |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $462.04 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $368.45 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $294.42 | 2019-2024 | Arazlo, Jublia, Duobrii |
| Incyte Corporation | $290.28 | 2021-2025 | Opzelura |
| Merz North America, INC. | $175.48 | 2022 | |
| Dermira, INC. | $107.15 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.73 | 2023-2025 | Spevigo |
| Organon LLC | $101.62 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $85.34 | 2022 | |
| Arcutis Biotherapeutics, INC. | $74.09 | 2024-2025 | Zoryve |
| Dermavant Sciences, INC. | $73.06 | 2023-2024 | Vtama |
| Strata Skin Sciences, INC. | $52.99 | 2019-2020 | |
| Biofrontera INC. | $38.16 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Helsinn Therapeutics (U.S.), INC. | $31.19 | 2023-2024 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyndsay Shipp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.